News

As per the pact, OctoPlus is expected to develop a controlled release formulation of an undisclosed compound using its proprietary drug delivery technology PolyActive, a biodegradable polymeric drug

Under the 4-year agreement, the KIF6 test kit manufactured by Celera, will be distributed by Abbott in the European Union and other geographic areas excluding the US. The

Ligand is expected to receive an upfront payment and continue to be entitled to receive potential future milestone and royalty payments. Ligand Pharma president and CEO John Higgins

The company has posted a operating loss of £6.91m the six months ended 2010, compared to operating loss of £3.61m, for the comparable period in 2009. Silence Therapeutics

Most recently, Biller has worked for Novartis as the vice president and head of global discovery chemistry at the Novartis Institutes for BioMedical Research (NIBR). Befor joining Novartis,

Afatinib is an oral compound targeted therapy that irreversibly inhibits both the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour

As per the terms of the license agreement, GLG Pharma has agreed to pay Moffitt when various commercialisation milestones are reached, as well as make royalty payments on

The Phase II clinical trial, coordinated by AGTC, is being conducted at The University of Massachusetts by Terrence Flotte and Cincinnati Children’s Hospital Medical Center by Bruce Trapnell.

Aricept transdermal patch NDA, if approved, is expected to be marketed by Eisai Inc, Easai’s US subsidiary, where it will co-promote the patch in collaboration with Pfizer. Easai